AI Cuts Weeks Off Drug Discovery for Cancer, Heart Disease

Finding new medicines just got faster and smarter, giving hope to millions waiting for treatments.

Bristol Myers Squibb partnered with NVIDIA to deploy one of the most powerful AI systems in medical research. The new infrastructure, called DGX SuperPOD, uses 10 times less energy while delivering breakthrough computing power for drug discovery.

The impact goes far beyond saving electricity. AI agents now automatically handle target identification and validation, tasks that used to consume weeks of scientists' time. Researchers can now spend their days testing bold hypotheses instead of sorting through mountains of data.

The company's "Predict First" approach uses AI to forecast which experiments will succeed before any lab work begins. This strategy now guides every small molecule program and most large molecule programs at BMS, helping scientists make confident decisions faster.

The technology already supports research across cancer, blood disorders, heart disease, immune conditions, and brain disorders. After nearly three years of collaboration, BMS continues expanding what AI can do for patients waiting for breakthrough treatments.

"This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis," said Robert Plenge, Chief Research Officer at BMS. Scientists spend less time on repetitive tasks and more time on questions requiring human judgment and creativity.

The Ripple Effect

The system creates a continuous learning loop that spans from initial target identification all the way through clinical trials. Each experiment teaches the AI something new, making the next round of predictions even sharper.

This hybrid intelligence model puts AI and human researchers side by side as partners. The expanded computing platform will train next generation foundation models on BMS's proprietary scientific data, combining machine speed with human insight.

The energy efficiency matters too. Delivering 10 times greater performance per megawatt means researchers can tackle larger AI workloads without dramatically increasing power consumption, making sustainable innovation possible.

Faster drug discovery means patients could see new treatment options reach clinics sooner, transforming years of waiting into months of hope.